Loratadine

證據等級: L5

預測適應症: 10 個

Loratadine: From Antihistamine Therapy to Allergic Urticaria

One-Sentence Summary

Loratadine is a second-generation H1-antihistamine. The TxGNN model’s top prediction for this drug is Allergic Urticaria, which — based on the evidence pack’s own mechanistic analysis — is best understood as a known-use reconfirmation of the antihistamine class rather than a novel repurposing hypothesis. This is supported by 3 clinical trials and 18 publications currently on file, though none directly test Loratadine itself against allergic urticaria as a primary efficacy endpoint.

Quick Overview

Item	Content
Original Indication	Not returned by the regulatory data sources in this evidence pack (see note below)
Predicted New Indication	Allergic Urticaria
TxGNN Prediction Score	98.98%
Evidence Level	L1
Australia Market Status	Not marketed (per available registry data)
Number of ARTG Entries	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available as a structured field for this drug (flagged as a data gap, DG002). Based on the evidence supplied with this candidate, Loratadine is a second-generation H1-histamine receptor antagonist. Allergic urticaria is primarily driven by mast-cell degranulation and histamine release acting on H1 receptors, so the mechanistic link between drug and indication is direct.

Importantly, the evidence pack itself notes this is not a genuinely novel repurposing signal: second-generation antihistamines, including loratadine, are an established drug class for urticaria internationally, so this prediction largely reconfirms already-known pharmacology rather than surfacing a new therapeutic hypothesis.

No Taiwan/TGA regulatory license records were returned for this drug in this evidence pack (market_status: 未上市, 0 ARTG entries), so the original approved indication could not be extracted from local regulatory sources. This should be treated as a data gap rather than evidence that no original indication exists.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT00762983	N/A (post-marketing survey)	Completed	1,003	Claritin (loratadine) tablet/RediTabs/dry syrup pediatric drug-use investigation; collected ADR frequency and safety/effectiveness factors in children
NCT00757562	Phase 3	Completed	97	Multiple-dose safety/tolerance of desloratadine (loratadine’s active metabolite) in atopic children and children with chronic idiopathic urticaria who are poor metabolizers

Note: a third hit (NCT07101445, motixafortide premedication study) was excluded — it was flagged in the evidence pack as unrelated to loratadine/urticaria (keyword-matching noise).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35396016	2022	Review	Profiles of Drug Substances, Excipients and Related Methodology	Comprehensive profile of loratadine; notes its use in allergic rhinitis, chronic urticaria and asthma
7528133	1994	Review	Drugs	Reappraisal of loratadine’s pharmacology and therapeutic use, including urticaria; superior to placebo, comparable to other antihistamines
16278258	2005	Review	Annals of Pharmacotherapy	Reviews oral antihistamines (loratadine class) for allergic rhinitis and chronic idiopathic urticaria management
16329713	2005	Review	Drug Safety	Safety/efficacy of desloratadine (active metabolite) across allergic disease including chronic idiopathic urticaria
18336052	2008	Review	Clinical Pharmacokinetics	Comparative PK/PD of desloratadine, fexofenadine and levocetirizine in allergic rhinitis/chronic idiopathic urticaria
9951950	1999	Review	Drugs	Comparative review of second-generation antihistamines, including loratadine
7530629	1994	Review	Drugs	General review of urticaria recognition, causes and antihistamine-based treatment
39549290	2024	Cohort	Iranian Journal of Allergy, Asthma, and Immunology	Dose-comparison of desloratadine combined with nasal steroid in allergic rhinitis; notes higher antihistamine doses recommended for urticaria control
12113226	2002	Review	Clinical Allergy and Immunology	H1-antihistamine use in children, primarily allergic rhinoconjunctivitis
40490797	2025	Mechanistic study	Chinese Medicine	Network pharmacology study of a TCM formula in chronic urticaria; mast-cell/immune mechanism context

Australia Market Information

No ARTG entries were returned for Loratadine in this evidence pack (total_licenses: 0, market_status: 未上市). This should be confirmed directly against the TGA ARTG database, as it may reflect a data collection gap rather than true absence from the Australian market.

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information. Structured warnings, contraindications and drug-interaction data were not available in this evidence pack (flagged as a Blocking data gap — DG001: TFDA/TGA label warnings and contraindications must be sourced before this candidate can complete initial safety screening).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic link is strong and well-supported by the antihistamine literature, and one completed Phase 3 trial plus a large completed post-marketing survey exist — but the underlying data pack also indicates this is largely a reconfirmation of already-established antihistamine use rather than a new discovery, and a blocking safety data gap (PI warnings/contraindications) prevents formal safety sign-off.

To proceed, the following is needed:

TGA-approved Product Information (warnings, contraindications) — currently blocking
Confirmed mechanism-of-action documentation (currently a data gap)
Verification of ARTG registration status for loratadine-containing products in Australia
Drug-drug interaction data (current query returned no results)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.